KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accumulated Expenses (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Accumulated Expenses data on record, last reported at $29.2 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 52.07% year-over-year to $29.2 million; the TTM value through Sep 2025 reached $29.2 million, up 52.07%, while the annual FY2024 figure was $22.6 million, 50.57% down from the prior year.
  • Accumulated Expenses reached $29.2 million in Q3 2025 per PACB's latest filing, up from $26.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $45.7 million in Q4 2023 and bottomed at $594000.0 in Q4 2021.
  • Average Accumulated Expenses over 5 years is $24.7 million, with a median of $24.9 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 96.58% in 2021, then surged 5387.54% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $594000.0 in 2021, then soared by 5387.54% to $32.6 million in 2022, then soared by 40.23% to $45.7 million in 2023, then crashed by 50.57% to $22.6 million in 2024, then rose by 29.11% to $29.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $29.2 million in Q3 2025, $26.5 million in Q2 2025, and $29.3 million in Q1 2025.